MX9401225A - Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion. - Google Patents

Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.

Info

Publication number
MX9401225A
MX9401225A MX9401225A MX9401225A MX9401225A MX 9401225 A MX9401225 A MX 9401225A MX 9401225 A MX9401225 A MX 9401225A MX 9401225 A MX9401225 A MX 9401225A MX 9401225 A MX9401225 A MX 9401225A
Authority
MX
Mexico
Prior art keywords
influenza
humans
preparation
vaccine composition
prevent infection
Prior art date
Application number
MX9401225A
Other languages
English (en)
Inventor
Robert J Gyurick
Nathalie Marie-Josephe
Claude Garcon-Johnson
Susan Dillon
Hirotoshi Nishikawa
Paul Dal Monte
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Biolog filed Critical Smithkline Beecham Corp
Publication of MX9401225A publication Critical patent/MX9401225A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona composiciones de vacuna capaces de mejorar una respuesta protectora a un antígeno de influenza seleccionado, la composición contiene por lo menos el antígeno y 3D-MPL, y métodos para mejorar la respuesta inmune a la influenza utilizando estas composiciones.
MX9401225A 1993-02-19 1994-02-17 Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion. MX9401225A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2153593A 1993-02-19 1993-02-19
US11575093A 1993-09-01 1993-09-01

Publications (1)

Publication Number Publication Date
MX9401225A true MX9401225A (es) 1994-08-31

Family

ID=26694802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9401225A MX9401225A (es) 1993-02-19 1994-02-17 Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.

Country Status (9)

Country Link
EP (1) EP0684838A1 (es)
AP (1) AP431A (es)
AU (1) AU6141094A (es)
CA (1) CA2156525A1 (es)
IL (1) IL108681A0 (es)
MA (1) MA23118A1 (es)
MX (1) MX9401225A (es)
SI (1) SI9400085A (es)
WO (1) WO1994019013A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
CZ289476B6 (cs) * 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6261573B1 (en) * 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
JP2004536785A (ja) * 2001-02-23 2004-12-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規なワクチン
EP1361890B1 (en) 2001-02-23 2011-03-30 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
GB2386072A (en) * 2001-04-27 2003-09-10 Becton Dickinson Co Novel vaccine
SI2179744T1 (sl) 2004-09-09 2011-04-29 Novartis Vaccines & Diagnostic Zmanjševanje potencialnih iatrogenih tveganj, povezanih z influenčnimi cepivi
EP1807116B1 (en) 2004-11-03 2015-05-06 Novartis Vaccines and Diagnostics, Inc. Influenza vaccination
DK1861120T3 (en) 2005-03-23 2016-07-25 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
BRPI0721393B8 (pt) * 2007-03-22 2022-09-06 Fund Butantan método para obter lipídeo a monofosforilado da bordetella pertussis como um subproduto da produção de vacina celular contra coqueluche
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
KR20100135766A (ko) * 2008-03-18 2010-12-27 노파르티스 아게 인플루엔자 바이러스 백신 항원 제조의 개선
EP3012330A1 (en) 2010-09-07 2016-04-27 Novartis AG Generic assays for detection of mammalian reovirus
WO2015147899A1 (en) * 2014-03-25 2015-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Army Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
JP7391959B2 (ja) 2018-07-10 2023-12-05 セキラス ピーティーワイ リミテッド 凝集物の除去
CN112361796A (zh) * 2020-11-13 2021-02-12 安徽省天长市周氏羊业有限公司 一种秸秆回收储存前破碎干燥装置
CN114989269B (zh) * 2022-06-30 2023-09-19 天康制药股份有限公司 一种牛赤羽免疫原性抗原及疫苗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
US5230899A (en) * 1985-08-07 1993-07-27 Smithkline Beecham Corporation Methods and compositions for making liposomes
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
AU627226B2 (en) * 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
DK425789A (da) * 1988-08-31 1990-03-01 Smithkline Beecham Corp Vaccinale polypeptider
AU640348B2 (en) * 1988-08-31 1993-08-26 Smithkline Beecham Corporation Vaccinal Polypeptides
KR100194079B1 (ko) * 1990-09-28 1999-06-15 장 스테판느 Hiv 감염 예방 또는 치료용 제약학적 조성물 및 이의 제조방법
JPH06503821A (ja) * 1990-12-20 1994-04-28 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） Ｂ型肝炎表面抗原に基づくワクチン
FR2671974A1 (fr) * 1991-01-24 1992-07-31 Pasteur Merieux Serums Vacc Composition vaccinale contre la grippe, a effet synergique, contenant comme additif du core de virus grippal.
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
PL170980B1 (pl) * 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL

Also Published As

Publication number Publication date
CA2156525A1 (en) 1994-09-01
MA23118A1 (fr) 1994-10-01
SI9400085A (en) 1994-09-30
AP9400621A0 (en) 1994-04-30
AU6141094A (en) 1994-09-14
EP0684838A1 (en) 1995-12-06
AP431A (en) 1995-11-15
IL108681A0 (en) 1994-05-30
WO1994019013A1 (en) 1994-09-01

Similar Documents

Publication Publication Date Title
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
DK0528859T3 (da) Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer
ES2184769T3 (es) Metodos y composiciones para microencapsulacion de antigenos para utilizar como vacunas.
TR200806258T2 (tr) Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
HUP0101047A1 (hu) Kombinált vakcinakészítmények
AR003006A1 (es) Composición de vacuna combinada que comprende un polisacarido capsular de haemophilus influenzae b conjugado con una proteina portadora adsorbido sobre fosfato de aluminio y uno u otros antígenos distintos, métodos para producirla, y su uso para preparar un medicamento
ES2092306T3 (es) Adyuvante para vacunas.
ATE223702T1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
MX9201245A (es) Nueva formulacion de vacuna para tratar infecciones cuasadas por el virus de herpes simple.
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
AU4622693A (en) Potentiation of immunogenic response
EA199900069A1 (ru) Вакцинная композиция против малярии
BR9907883A (pt) Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica
AR001618A1 (es) Adyuvante de saponina del arbol quillajay y formulacion de vacuna que contiene el mismo
BRPI0113155B8 (pt) métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b
ES2530510T3 (es) Constructos peptídicos sintéticos para el diagnóstico y tratamiento de periodontitis asociada con Porphyromonas gingivalis
DK1666057T3 (da) Fremgangsmåde til fremstilling af en acellulær vaccine indeholdende Bordetella pertussis antigener
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
PT1238086E (pt) Vacina para aumentar as respostas imunes a vacina contra virus herpes simples
ATE322285T1 (de) Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu